Merck (MRK) and Pfizer (PFE) enter into a 60/40 worldwide agreement to jointly develop and...


Merck (MRK) and Pfizer (PFE) enter into a 60/40 worldwide agreement to jointly develop and commercialize PFE's type 2 diabetes treatment ertugliflozin which should enter Phase III trials later this year. As part of the deal, PFE received $60M upfront and may receive additional payments in the future. (PR)

From other sites
Comments (3)
  • tplatek
    , contributor
    Comments (2) | Send Message
     
    One has to wonder why PFE is doing a joint venture with MCK when it certainly can afford to do it solo.
    29 Apr 2013, 10:02 AM Reply Like
  • biochemist
    , contributor
    Comments (761) | Send Message
     
    If you read the press release the answer to your question is quite clear. The agreement is not only for co-marketing ertugliflozin but also for developing fixed-dose combination tablets with metformin and sitagliptin. Plus, MRK has an established leadership in diabetes care due to Januvia/Janumet.
    29 Apr 2013, 05:06 PM Reply Like
  • wumpsie
    , contributor
    Comment (1) | Send Message
     
    more Merck/PFE collaboration in the future? -- leading in to possible merger?
    29 Apr 2013, 02:21 PM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs